17 HANOVER SQUARE, LONDON, X0
Provides Update on DiamiR Biosciences Merger
Amended material disclosure
Announces Shareholder Approval of Proposed Merger with DiamiR Biosciences
Material disclosure
Files Pre-Effective Amendment No. 2 to Form S-4 Registration Statement
Announces Voting Results from 2025 Annual Meeting of Shareholders
Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
S-4/A
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
No filings found
Schedule 13D - Ownership Report
Initial Statement of Beneficial Ownership
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Post-Effective Amendment to Registration Statement
Delisting Amendment
Submission Upload
Correspondence